Company / R&D Expense
CAPRICOR THERAPEUTICS, INC. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$84.5M
FY2025
5-year range
$13.6M / $84.5M
FY2021-FY2025
Trend
+69.0%
vs FY2024
Sector context
#152 of 210
Health Care
What the data says
At $84M, CAPRICOR THERAPEUTICS, INC.'s r&d expense ranks #152 of 210 in the Health Care sector. R&D Expense has increased for 5 consecutive years, from $8M in FY2020 to $84M in FY2025.
Based on SEC 10-K filings.
$84M in FY2025 with a 5-year CAGR of +58.4%.
Improved from $36M to $84M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +57.0%
- 5-Year CAGR
- +58.4%
- 10-Year CAGR
- -
Sector benchmark
#152 of 210 in Health CareTop 72% of 210This company $84.5M Sector average $644.1M
▼
-86.9% below sector average
Key checks
Key Insights
- CAPRICOR THERAPEUTICS, INC.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +58.4%, indicating consistent growth.
- In FY2025, r&d expense increased 69.0% year-over-year.
- Ranks #152 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $84.5M | +69.0% |
| FY2024 | $50.0M | +37.1% |
| FY2023 | $36.4M | +67.1% |
| FY2022 | $21.8M | +60.8% |
| FY2021 | $13.6M | +60.5% |
| FY2020 | $8.5M | -29.9% |
| FY2019 | $12.1M | +0.0% |
| FY2018 | $12.1M | +12.1% |
| FY2017 | $10.8M | -32.9% |
| FY2016 | $16.0M | +16.6% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026